Nifedipine, a calcium antagonist with relaxant effects on the myometrium, didn't significantly improve the success of external cephalic version in women with a fetus in breech presentation, according to research published in the August issue of Obstetrics and Gynecology.
Nifedipine, a calcium antagonist with relaxant effects on the myometrium, didn't significantly improve the success of external cephalic version in women with a fetus in breech presentation, according to research published in the August issue of Obstetrics and Gynecology.
Marjolein Kok, MD, of the Academic Medical Centre in Amsterdam, the Netherlands, and colleagues analyzed data from 310 women with a breech presentation singleton fetus at a gestational age of 36 weeks or later. The women were randomized to receive nifedipine or placebo before the attempted external cephalic version. Women in the treatment group received 10 mg of the drug 30 and 15 minutes before the procedure.
The researchers found no significant difference in success rates for the procedure between the groups and no significant difference in the rates of cesarean delivery in the women.
“Cephalic presentation after external cephalic version in our study was not different from the success rates of the placebo groups described in other studies ranging from 28% to 68%. Therefore, we feel confident that the external cephalic version was carried out properly. In addition, the cesarean delivery rate for breech presentation in this trial was 68%. After external cephalic version in 310 women, 120 delivered vaginally in cephalic position. Thus, our study confirms the benefits of external cephalic version in the reduction of maternal and neonatal complications,” the authors write.
Kok M, Bais JM, van Lith JM, et al. Nifedipine as a uterine relaxant for external cephalic version. A randomized controlled trial. Obstet Gynecol. 2008;112:271-276
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More